Axsome Therapeutics AXS-05 Meets Primary Endpoint in Phase 2 Trial for Major Depressive Disorder Treatment

Axsome Therapeutics recently announced that its novel drug AXS-05 met its primary endpoints in a Phase 2 trial, that could see the drug have a major positive impact on the major depressive disorder population. <br />